# Kyverna Therapeutics Inc. (KYTX)

Source: https://www.quantisnow.com/company/KYTX
Generated: 2026-11-19T07:43:31.807Z

- Ticker: KYTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2024
- SEC CIK: 0001994702

## Latest KYTX news and filings

- 2026-11-16 17:11 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-kyverna-therapeutics-inc-6793441)
- 2026-11-12 13:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kyverna-therapeutics-inc-6786529)
- 2026-11-12 13:01 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6786511)
- 2026-11-12 13:00 UTC [Earnings] [Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/kyverna-therapeutics-announces-completion-of-bla-submission-for-miv-cel-in-6786403)
- 2026-11-09 16:00 UTC [Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology](https://www.quantisnow.com/insight/kyverna-therapeutics-announces-publication-of-registrational-miv-cel-data-in-patients-6780761)
- 2026-11-05 21:02 UTC [Conference Announcement] [Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference](https://www.quantisnow.com/insight/kyverna-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-6775943)
- 2026-10-23 14:30 UTC [Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026](https://www.quantisnow.com/insight/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-6756050)
- 2026-10-21 11:15 UTC [Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto](https://www.quantisnow.com/insight/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-6752869)
- 2026-10-19 18:29 UTC [SEC Form SCHEDULE 13G filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-kyverna-therapeutics-inc-6750432)
- 2026-10-07 12:00 UTC [Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026](https://www.quantisnow.com/insight/kyverna-therapeutics-to-present-positive-data-in-stiff-person-syndrome-6739717)
- 2026-09-24 10:00 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6724695)
- 2026-09-24 10:00 UTC [Earnings Date] [Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis](https://www.quantisnow.com/insight/kyverna-therapeutics-reports-positive-one-year-data-demonstrating-durable-clinical-responses-6724639)
- 2026-09-02 20:05 UTC [Conference Announcement] [Kyverna Therapeutics to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/kyverna-therapeutics-to-present-at-upcoming-investor-conferences-6703045)
- 2026-08-14 11:00 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-kyverna-therapeutics-inc-6681775)
- 2026-08-11 20:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kyverna-therapeutics-inc-6675760)
- 2026-08-11 20:04 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6675701)
- 2026-08-11 20:02 UTC [Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/kyverna-therapeutics-reports-pipeline-progress-and-second-quarter-2026-financial-6675589)
- 2026-07-27 12:00 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6649045)
- 2026-07-27 12:00 UTC [Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel](https://www.quantisnow.com/insight/kyverna-therapeutics-and-elevatebio-enter-into-commercial-manufacturing-and-supply-6649000)
- 2026-07-09 10:00 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6632223)
- 2026-06-22 12:00 UTC [Leadership Update] [Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition](https://www.quantisnow.com/insight/kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal-and-compliance-6610036)
- 2026-06-03 12:00 UTC [Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis](https://www.quantisnow.com/insight/kyverna-therapeutics-highlights-updated-miv-cel-data-at-eular-demonstrating-substantial-6585857)
- 2026-06-02 20:30 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6584511)
- 2026-05-29 20:30 UTC [SEC Form 4] [Director Cohen Fred E was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-cohen-fred-e-was-granted-5093-shares-increasing-direct-6579480)
- 2026-05-29 20:30 UTC [SEC Form 4] [Director Clark Ian T was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-clark-ian-t-was-granted-5093-shares-increasing-direct-6579477)
- 2026-05-29 20:30 UTC [SEC Form 4] [Director Seidenberg Beth C was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-seidenberg-beth-c-was-granted-5093-shares-increasing-direct-6579459)
- 2026-05-29 20:30 UTC [SEC Form 4] [Executive Chairperson Shaw Christi covered exercise/tax liability with 4,194 shares, decreasing direct ownership by 6% to 66,741 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/executive-chairperson-shaw-christi-covered-exercisetax-liability-with-4194-shares-6579452)
- 2026-05-29 20:30 UTC [SEC Form 4] [Director Aktar Mert was granted 5,093 shares, increasing direct ownership by 31% to 21,727 units (SEC Form 4)](https://www.quantisnow.com/insight/director-aktar-mert-was-granted-5093-shares-increasing-direct-ownership-6579445)
- 2026-05-20 20:30 UTC [SEC Form 3] [SEC Form 3 filed by new insider Martini Gregory S.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-martini-gregory-s-6565394)
- 2026-05-20 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Martini Gregory S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-martini-gregory-6565388)
- 2026-05-18 12:00 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-leadership-update-other-6559209)
- 2026-05-18 12:00 UTC [Leadership Update] [Kyverna Therapeutics Names Greg Martini as Chief Financial Officer](https://www.quantisnow.com/insight/kyverna-therapeutics-names-greg-martini-as-chief-financial-officer-6559163)
- 2026-05-14 12:00 UTC [Conference Announcement] [Kyverna Therapeutics to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/kyverna-therapeutics-to-present-at-upcoming-investor-conferences-6552493)
- 2026-05-12 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kyverna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kyverna-therapeutics-inc-6548028)
- 2026-05-12 20:05 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6547939)
- 2026-05-12 20:02 UTC [Leadership Update] [Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results](https://www.quantisnow.com/insight/kyverna-therapeutics-announces-initiation-of-rolling-sps-bla-submission-and-6547749)
- 2026-05-06 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Dac Nadia](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-dac-nadia-6535986)
- 2026-05-06 20:30 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dac Nadia](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dac-nadia-6535956)
- 2026-05-04 12:00 UTC [SEC Form 8-K] [Kyverna Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kyverna-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6528077)
- 2026-05-04 12:00 UTC [Leadership Update] [Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer](https://www.quantisnow.com/insight/kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology-6528065)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KYTX
- Earnings history: https://www.quantisnow.com/earnings/KYTX
- Dividend history: https://www.quantisnow.com/dividends/KYTX
- Insider transactions: https://www.quantisnow.com/insiders/KYTX
- Options chain: https://www.quantisnow.com/options/KYTX
- SEC 8-K filings only: https://www.quantisnow.com/company/KYTX/8-k
- RSS and alerts for KYTX: https://www.quantisnow.com/docs/rss-feeds.md
